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Abstract
Missing outcome data due to loss to follow-up occurs frequently in clinical cohort studies of HIV-infected patients.
Censoring patients when they become lost can produce inaccurate results if the risk of the outcome among the censored
patients differs from the risk of the outcome among patients remaining under observation. We examine whether patients
who are considered lost to follow up are at increased risk of mortality compared to those who remain under observation.
Patients from the US Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) who newly initiated
combination antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived for at least one year were
included in the study. Mortality information was available for all participants regardless of continued observation in the
CNICS. We compare mortality between patients retained in the cohort and those lost-to-clinic, as commonly defined by a
12-month gap in care. Patients who were considered lost-to-clinic had modestly elevated mortality compared to patients
who remained under observation after 5 years (risk ratio (RR): 1.2; 95% CI: 0.9, 1.5). Results were similar after redefining loss-
to-clinic as 6 months (RR: 1.0; 95% CI: 0.8, 1.3) or 18 months (RR: 1.2; 95% CI: 0.8, 1.6) without a documented clinic visit. The
small increase in mortality associated with becoming lost to clinic suggests that these patients were not lost to care, rather
they likely transitioned to care at a facility outside the study. The modestly higher mortality among patients who were lost-
to-clinic implies that when we necessarily censor these patients in studies of time-varying exposures, we are likely to incur at
most a modest selection bias.
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Introduction
Missing outcome data from loss to follow-up occurs in both
randomized trials and observational studies [1]. The validity of
treatment (or exposure) effects is questionable in cohort studies
with high amounts of loss to follow-up. In clinical cohort studies of
HIV-infected patients, the evaluations of time-varying exposures,
biomarkers and clinical events are typically precluded when
patients cease to return for care.
In clinical HIV cohort studies, censoring is often defined by
failing to return for care at a specific clinic for a pre-specified
interval of time, typically ranging from 3 to 18 months. After
censoring, a patient’s hazard of the outcome is assumed to be the
same as the hazard for comparable patients who remain under
observation [2]. If this assumption is violated, estimates of the
incidence of the outcome or the effect of an exposure on the
outcome may be biased. For example, if patients who are lost from
the study clinic (henceforth, lost-to-clinic) do not seek care
elsewhere, they may have a higher risk of mortality compared to
patients who remain under observation. As an alternate example,
there may be unmeasured common causes of patients becoming
lost-to-clinic and the outcome, such as socioeconomic status. Here,
we investigate whether patients who are considered lost-to-clinic
are at increased risk of 5-year mortality compared to those who




The Centers for AIDS Research Network of Integrated Clinical
Systems (CNICS) was developed to maintain a comprehensive and
standardized clinical data repository to support population-based
HIV research in the United States [3]. The CNICS cohort
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includes over 27,000 HIV-positive adults engaged in clinical care
from January 1, 1995 to the present at 8 CFAR sites (Case
Western Reserve University; Fenway Community Health Center
of Harvard University; Johns Hopkins University; University of
Alabama at Birmingham; University of California, San Diego;
University of California, San Francisco; University of North
Carolina; and University of Washington). Institutional review
boards at each site approved study procedures. Participants
provided written informed consent to be included in the CNICS
cohort or contributed administrative and/or clinical data with a
waiver of written informed consent where approved by local
institutional review board(s).
All patients attending 2 primary HIV medical care visits at study
sites are included in CNICS and followed longitudinally while they
remain in care at study sites. The average time between follow up
visits is 3 months, however, patients can be seen more or less often
depending on clinical care. CNICS is a dynamic cohort with
approximately 1400 new patients enrolling and 10% of existing
patients becoming lost to the cohort each year [3]. There is no
CNICS-wide systematic approach to assess the disposition of
patients lost-to-clinic to determine if they are truly out of HIV care
or have transferred care to another medical clinic, though efforts
to track patients lost-to-clinic have been undertaken at specific sites
[4]. CNICS provides open access to data through its concept
review process (www.uab.edu/cnics). The CNICS includes 12,590
patients who entered care at a CNICS site between January 1,
1999 and December 31, 2009 and had not previously initiated
combined antiretroviral therapy. Of these 12,590 patients, we
included 7635 patients who newly initiated combination antiret-
roviral therapy and had measured CD4 cell count and viral load
between these dates. Therapy initiation was defined as the date of
initiation of a regimen consisting of three or more antiretroviral
agents. We did not exclude patients with documented prior mono/
dual antiretroviral therapy exposure. Of the 7635 patients newly
initiating therapy, 7183 (93%) survived for at least one year and
were eligible for inclusion in the analysis of the relationship
between becoming lost-to-clinic and death.
Lost-to-clinic
In analyses of the CNICS and other cohorts, patients are
sometimes censored after 12 months without a documented clinic
visit. To determine if the risk of mortality differed between person-
time that is censored and person-time that is included in such a
study, we compared the risk of mortality between patients who had
experienced a 12-month gap in care with the risk of mortality
among patients who had not yet experienced a 12-month gap in
care. After patients had a 12-month gap in care, we considered
them to be lost-to-clinic throughout the remainder of the study
period, as patients who are censored are usually not allowed to re-
enter study. We quantify the amount of misclassified person-time
due to patients returning to the clinic after a 12-month gap in care
in the discussion. We also perform a sensitivity analysis in which
the definition of ‘‘loss to care’’ was varied to 6 months and 18
months without a documented clinic visit.
Mortality ascertainment
The outcome of interest was all-cause mortality. Each CNICS
site maintains a registry of deaths among patients at that site and
semiannually queries the United States Social Security Death
Index and/or National Death Index to confirm reported deaths
and record deaths not captured by the CNICS sites. Mortality
records were linked to CNICS patients using approved Social
Security Death Index and National Death Index matching
criteria, including combinations of first and last names, father’s
surname, social security number, and month and year of birth.
Deaths among patients are captured in these queries regardless of
lost-to-clinic status. Because surveillance for mortality is conducted
using national registries, outcome ascertainment is uniform across
the study sites.
Deaths were considered to occur ‘‘in care’’ unless they occurred
after a 12-month gap in care. After a 12-month gap in care, deaths
were classified as lost-to-clinic. Because delays in reporting to the
vital status registries could give the appearance of artificially low
mortality among patients lost-to-clinic (and thus not captured in
clinical death registries) in the most recent years of data, we
administratively censored all patients on December 31, 2010 to
allow adequate time for deaths to be reported to Social Security
Death Index or National Death Index and CNICS.
Statistical methods
All patients were in care at a study clinic at ART initiation by
definition and were eligible to become lost to clinic after surviving
for one year. Patients were followed from one year after ART
initiation until death, December 31, 2010, or 6 years after ART
initiation, for a maximum follow-up time of 5 years. Patients at
two study sites were censored on December 31, 2009 due to
incomplete visit data in 2010.
We compared cumulative incidence of mortality between
patients remaining in care at a study clinic and those who were
lost-to-clinic using risk ratios and risk differences [5]. To estimate
the effect of becoming lost-to-clinic on mortality in the presence of
time-varying confounding, we used marginal structural models to
estimate risk ratios and risk differences that were standardized to
the total study sample. Standardized risk ratios and risk differences
were estimated using stabilized inverse probability weights [6–8]
constructed from a pooled logistic regression model for becoming
lost-to-clinic, with time coarsened to the month. Weights were
estimated using time-fixed and time-varying covariates. Time-
fixed covariates were measured at baseline one year after therapy
initiation and included sex, age, race, ethnicity, AIDS status,
history of single or two-drug antiretroviral therapy, sexual
orientation, injection drug use, CD4 cell count and viral load,
and calendar date of ART initiation. Time-varying factors were
updated monthly and included the patient’s AIDS status, CD4 cell
count, and viral load (averaged over the previous month).
Continuous variables (age, CD4 cell count, viral load, and
calendar date of ART initiation) were modeled using restricted
quadratic splines with 4 knots placed at the 5th, 35th, 65rd, and 95th
percentiles [9]. Because lost-to-clinic was defined after a 12-month
absence, time-varying covariates were lagged 12 months in the
models for becoming lost-to-clinic used to construct the weights.
The inverse probability weights had a mean of 1.00 (standard
deviation: 0.34) and ranged from 0.24 to 9.25. The standardized
mortality estimates were calculated using the complements of the
Kaplan-Meier survival curves in the weighted data [10]. Ninety-
five percent confidence intervals for risk ratios and risk differences
were calculated using standard errors estimated by the standard
deviation of the effect measures in 200 nonparametric bootstrap
[11] samples with replacement of the original study sample size.
Statistical analyses were performed using SAS version 9.3 (SAS
Institute, Inc., Cary, NC).
Results
Table 1 describes the characteristics of the 7183 patients at
study entry one year after ART initiation and during 25,581
person-years of follow-up. At the start of follow up, 18% of patients
were female, 39% were African-American, 94% were mono/dual
Loss-to-Clinic and Mortality
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antiretroviral-therapy naı̈ve, and 32% had a prior AIDS diagnosis.
The median calendar year was 2004 (IQR: 2001, 2007), and the
median age was 39 years (IQR: 33, 35). At baseline, the median
CD4 cell count was 326 (IQR: 50, 759), and 73% had a
suppressed viral load, defined as under 500 copies/mL. Among
the unsuppressed, the median log10 viral load was 4.4 (IQR: 3.6,
5.0).
Over the 25,581 person-years of follow-up, 3080 of 7183
patients experienced a 12-month gap in care, rendering them lost-
to-clinic by our definition. The cumulative incidence of lost-to-
clinic was 46% at 5 years (Figure 1). During the 17,897 person-
years contributed by patients in care at CNICS sites prior to their
first 12-month gap in care, the median CD4 cell count was 427
(IQR: 262, 617) and patients’ viral loads were suppressed for 79%
of the in-care person-years. The median log10 viral load during the
person-years in which patients’ viral loads were unsuppressed was
4.4 (IQR: 3.5, 5.0). By definition, CD4 cell count and viral load
measurements were not available during the 7684 person-years
lost to clinic, during which patients were not evaluated at CNICS
sites, but remained alive according to national vital status indices.
Over the 5 years of follow-up, 439 deaths occurred during the
17,987 person-years contributed by patients in care at CNICS
sites. During the same time-period, among the 7684 person-years
contributed by patients lost-to-clinic, 229 deaths occurred. Table 2
provides the crude and standardized 5-year cumulative mortality
risk, risk ratios, and risk differences for patients retained in care at
CNICS sites and those lost. The crude 5-year risk difference was
3.26% (95% CI: 0.99, 5.54) and risk ratio was 1.29 (95% CI: 1.09,
1.53) for patients lost-to-clinic relative to those remaining in care.
Because few measured variables predicted which patients became
lost-to-clinic, the estimated risk difference and risk ratio comparing
mortality for patients lost-to-clinic and those remaining in care
were relatively similar after standardization by baseline and time-
varying factors; the standardized 5-year risk difference was 2.22%
(95% CI: 21.38, 5.86) and risk ratio was 1.18 (95% CI: 0.92,
1.50). Figure 2 provides the crude and standardized cumulative
mortality curves for those retained continuously in care at CNICS
sites and those lost-to-clinic.
Results were similar under alternate definitions of loss to clinic.
When loss to clinic was defined as 6 months without a clinic visit,
the standardized 5-year risk ratio was 1.03 (95% CI: 0.84, 1.26)
and when loss to clinic was defined as 18 months without a clinic
visit, the standardized 5-year risk ratio was 1.16 (95% CI: 0.84,
1.60).
Table 1. Demographics and clinical characteristics at study entry one year after ART initiation and over 25,581 person-years of
follow-up among 7183 patients who initiated antiretroviral therapy between January 1, 1998 and December 31, 2009 and survived
for at least one year at 8 US clinical sites, followed for death up to 5 years.
Characteristics Study entry N = 7183 patients Retained in care n = 17897 person-years Lost to clinic n = 7684 person-years
n % % %
Male sex 5817 82 81 81
Black race 2830 39 40 39
Hispanic ethnicity 888 12 12 12
Injection drug user 1156 16 16 18
MSM 4092 57 56 55
Prior ARV use 460 6 7 8
AIDS 2279 32 38 – a
CD4 cell count
,250 2605 36 23 – a
250–500 2726 38 38 – a
.500 1852 26 39 – a
Suppressed viral loadb 1909 73 79 – a




Figure 1. Cumulative incidence of loss to clinic. Loss to clinic was
defined as a 12-month absence from CNICS clinics. The figure presents
loss to clinic among 7183 patients who initiated antiretroviral therapy
between January 1, 1998 and December 31, 2009 at 8 US clinical sites
and survived for at least one year, followed up for 5 years.
doi:10.1371/journal.pone.0102305.g001
Loss-to-Clinic and Mortality
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Discussion
In the CNICS cohort, the 5-year risk of becoming lost-to-clinic,
defined as a 12-month gap in care after surviving for 1 year from
combination ART initiation, was 46%. The large number of
patients with a 12-month gap in care by 5 years is a concern for
both clinicians and researchers. For clinicians, a patient becoming
lost-to-clinic for 12 months or longer may signal lack of access to
the health system, non-adherence to ART, and, subsequently,
greater plasma viremia conferring poor prognosis and higher
probability of transmission [12,13]. For researchers, patients who
are lost-to-clinic may not provide necessary outcome (and other)
data to include in studies, meaning that outcome data for patients
in care at study sites must represent the missing outcome data for
those who are lost-to-clinic. If patients lost-to-clinic have different
experiences than patients in care at CNICS sites, such studies
might produce inaccurate results [14,15].
However, in the CNICS cohort, patients who were lost-to-clinic
for 12 or more months had only 1.2 times the risk of mortality of
patients retained in care. The elevation in mortality among those
lost to clinic was modest compared to the effect seen in cohorts in
developing countries, where patients lost to clinic may have up to
10 times the risk of mortality of patients retained in care [16–19].
The difference in the effect of becoming lost to clinic in the
CNICS cohort and in developing countries could stem from
heterogeneity in both the reasons for becoming lost-to-clinic and
the experiences of patients after becoming lost to clinic. In both
settings, patients who are lost to a particular clinic may or may not
have disengaged from care entirely. For example, patients who
become lost to one clinic may have transferred to a different health
services provider and treatment center [20]. Other patients may
have become lost not only at the clinic of record but altogether,
resulting in cessation of all treatments, increased risk for
opportunistic infections, and earlier mortality [21,22]. While we
expect that our results are generalizable to clinical cohort studies
of patients with HIV in the United States, the modest increase in
mortality among patients lost to clinic in the CNICS may not be
generalizable to settings in which most or all patients who are lost
to clinic, in fact, become lost to care altogether.
In settings without comprehensive death registries, death itself
can be a reason that a patient becomes lost-to-clinic [23]. In this
situation, common in resource limited settings, we would expect to
observe a stronger association between those lost-to-clinic and
death than in settings, such as the CNICS, in which comprehen-
sive death registries are available. On the other hand, in settings
without a comprehensive death registry, deaths occurring after
patients become lost to clinic could be underreported if systematic
tracking efforts fail to recover all deaths among patients who are
lost [24].
In the CNICS cohort, reasons for absence from care and the
experiences of patients during gaps in care are unknown. The
modest increase in mortality among patients lost to clinic suggests
a large fraction of these patients are more likely to have transferred
to another health provider or to have re-engaged in care at a
CNICS site after a 12-month gap than to have become disengaged
from the health system entirely. In our analysis, we consider
patients to be lost to clinic after the first 12-month gap in clinic
visits in which the patient had a lab test (i.e., CD4 cell count or
viral load assessment) or initiated ART. Some patients returned to
care at a CNICS site later in the study period, but after patients
were classified as lost to clinic, we considered them to be lost
throughout the remainder of follow up, as this is how they would
typically be handled analytically by censoring. Person-time of
Table 2. Five-year risk ratios and risk differences comparing mortality between patients continuously retained in care at CNICS
sites and patients lost to clinic among 7183 patients who initiated antiretroviral therapy between January 1, 1998 and December
31, 2009 and survived for at least one year at 8 US clinical sites, followed for death up to 5 years.
Deaths Person-years Mortalitya RR (95% CIb) RD (95% CIb)
Crude In care 439 17896.76 10.99 1 0
Lost to clinic 229 7684.28 14.21 1.29 (1.09, 1.53) 3.26 (0.99, 5.54)
Standardizedc In care 487.2 18033.17 12.20 1 0
Lost to clinic 213.8 7479.18 14.06 1.18 (0.92, 1.50) 2.22 (–1.38, 5.86 )
CI, Confidence interval; RR, risk ratio; RD, risk difference.
aCumulative mortality risk was calculated as the complement of the Kaplan-Meier survival curve at 5 and 10 years.
bConfidence intervals based on 200 nonparametric bootstrap resamples.
cFor sex, age, race, ethnicity, AIDS status at baseline, antiretroviral-therapy-naive at baseline, sexual orientation, injection drug use at baseline, CD4 cell count, viral load
at baseline, and calendar date of ART initiation, and time-varying CD4 cell count, viral load, and AIDS status.
doi:10.1371/journal.pone.0102305.t002
Figure 2. Cumulative mortality for patients in care and lost to
clinic. Crude (grey) and standardized (black) survival curves compare
mortality between patients continuously retained in care at CNICS sites
(solid lines) and patients lost to clinic (dotted lines) among 7183
patients who initiated antiretroviral therapy between January 1, 1998
and December 31, 2009 and survived for at least one year at 8 US
clinical sites, followed for death up for 5 years.
doi:10.1371/journal.pone.0102305.g002
Loss-to-Clinic and Mortality
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patients who were lost but then returned to care is misclassified. In
the CNICS cohort, 39% (n = 1110) of the 2828 patients but only
10% of the person-years who became lost to clinic by our
definition returned to care at a site in the CNICS during the 5-
year study period. While we would be interested in comparing
mortality between patients who returned to care and patients who
remained lost to the clinic, we could not account for confounding
in such a comparison because predictors of return to care were not
measured after patients left care at a CNICS site. Notably, altering
the definition of becoming lost to clinic had only a modest impact
on the 5-year risk ratio.
A number of approaches have been developed to measure
retention in HIV care, with no clear gold standard established
[25]. Most prior studies evaluating the impact of HIV care
retention on health outcomes have measured retention over
relatively short observation periods, typically 1–2 years [26–28].
Here, we measure retention using 12-month gap by monitoring
participants for this event over a considerably longer 5-year
observation period. Our finding that almost half of CNICS
participants had a 12-month gap within 5 years of starting ART is
striking. Gaps of this length may become more common as
patients on stable therapy with suppressed viral load and high
CD4 cell counts may be seen by primary providers outside the
HIV clinic setting and only return to more specialized care at
greater intervals or when HIV specific treatment decisions are
needed. The reason for large gaps in cohort clinic participation
can be examined in those patients who reconnect to care. The
observation that 39% of those experiencing a 12-month gap re-
connect to care within the 5-year study period suggests that future
studies of this group may be informative [29].
The magnitude of the associations presented here reflects both
the effect of lost-to-clinic on mortality and the strength of the
unmeasured common causes of becoming lost-to-clinic and death.
While we included measured predictors in the estimation of the
standardizing weights, it is likely that unmeasured variables also
acted as predictors of both becoming lost-to-clinic and mortality.
For example, we did not account for income; if patients with lower
income were more likely to become lost-to-clinic and had higher
risk of mortality, then our estimates of the effect of loss-to-care on
mortality might have an upward bias.
Censoring patients who are lost-to-clinic is often necessary when
loss-to-clinic precludes observation of time-varying covariates or
outcomes. The higher mortality among patients with a 12-month
gap in care means that censoring patients who are lost-to-clinic for
12 or more months may result in an underestimate of absolute
mortality in the population under study [16,17]. In addition,
censoring patients who are lost-to-clinic may induce selection bias
in studies of treatment or exposure effects. For selection bias to
occur there must be: 1) selection (i.e. some patients must be lost-to-
clinic); 2) loss-to-clinic associated with exposure; and 3) loss-to-
clinic associated with the outcome [14]. While the first two
conditions above can usually be assessed in observed data, the
present work provides rare insight into the third condition, which
is typically not estimable in observed data. The modestly higher
mortality among patients who were lost-to-clinic implies that when
we necessarily censor these patients in studies of mortality or other
related outcomes, we are likely to incur at most a modest bias in
the risk or estimates of exposure effects on these outcomes.
However, if the association between loss-to-clinic and mortality is
due solely to the direct effect of loss-to-clinic on mortality, the
elevation in mortality among patients lost to clinic means only that
total effect of an exposure will differ from the effect of that
exposure estimated when patients lost to clinic are censored.
Beyond the methodological and analytic implications of our
findings for evaluation and inference from HIV clinical cohort
studies, we make novel observations of clinical and public health
importance. Our finding that an incident 12-month gap occurring
up to 5 years following ART start is associated with an elevated
mortality risk is germane to the contemporary HIV clinical, policy
and public health agenda [26]. In the context of HIV management
as a chronic disease and with increasing attention to the HIV care
continuum, evaluating the dynamic nature of retention in care
over the longer term is of the utmost importance.
Censoring patients when they become lost-to-clinic is often
necessary in HIV or other clinical cohort studies. Patients
becoming lost-to-clinic for 12 months or longer in the CNICS
cohort had modestly elevated risk of mortality when compared to
patients retained in care at CNICS sites. The small increase in
mortality associated with becoming lost to clinic suggests that these
patients were not lost to care, rather they likely transitioned to care
at a facility outside the study. Because the increase in mortality for
patients lost-to-clinic was small, censoring these patients is unlikely
to induce substantial selection bias in studies of mortality.
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